To acquire 23andMe’s Personal Genome Service, Total Health and Research Services business lines, and its Biobank and ...

American biotechnology firm Regeneron Pharmaceuticals is buying the personal genetics brand 23andMe after submitting a winning bid of $256 million in a bankruptcy auction, according to a Monday ...

Being spliced on to Regeneron will free the genetic testing company from its fatal dependence on sporadic revenue ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

Regeneron acquires 23andMe for $256 million following its bankruptcy. The deal includes DNA data access, raising privacy ...

The insolvent genetic analysis company 23andme is taken over by a pharmaceutical company that wants to continue the business ...

South San Francisco, California-based 23andMe filed for bankruptcy last month, seeking to sell its business at auction after ...

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...